Lower doses of 6-mercaptopurine/azathioprine bring enough clinical efficacy and therapeutic concentration of erythrocyte 6-mercaptopurine metabolite in Japanese IBD patients

Journal of Crohn's and Colitis

Volumn 2, Issue 4, 2008, Pages 315-321

  Komiyama, Takako ^a   Yajima, Tomoharu ^b   Kubota, Rie ^c   Iwao, Yasushi ^b   Sakuraba, Atsushi ^c   Funakoshi, Shinsuke ^c   Negishi, Kenichi ^a   Minami, Ikuko ^a   Tanaka, Yoichi ^a   Mae, Hiroshi ^a   Hibi, Toshifumi ^b  

^a School of Pharmacy   (Japan)

^b Institute for Advanced Medical Research   (Japan)

^c KITASATO INSTITUTE HOSPITAL   (Japan)

Author keywords

6 Mercaptopurine; 6 TGN level; Azathioprine; Inflammatory bowel disease; Japanese patients

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN; MERCAPTOPURINE; METHOTREXATE; TACROLIMUS; THIOPURINE METHYLTRANSFERASE;

ADULT; ARTICLE; CROHN DISEASE; DRUG EFFICACY; ENTERITIS; ERYTHROCYTE; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; REMISSION; ULCERATIVE COLITIS;

EID: 56449112965     PISSN: 18739946     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.crohns.2008.05.002     Document Type: Article

References (22)

1. Adler D.J., and Korelitz B.I. The therapeutic efficacy of 6-mercaptopurine in refractory ulcerative colitis. Am J Gastroenterol 85 (1990) 717-722
2. Pearson D.C., May G.R., Fick G.H., and Sutherland L.R. Azathioprine and 6-mercaptopurine in Crohn's disease: a meta-analysis. Ann Intern Med 123 (1995) 132-142
3. Lennard L. The clinical pharmacology of 6-mercaptopurine. Eur J Cli Pharmacol 43 (1992) 329-339
4. Dubinsky M.C., Lamothe S., Yang H.Y., Targan S.R., Sinnett D., ThÈorÍt Y., et al. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology 118 (2000) 705-713
5. Dubinsky M.C., Yang H., Hassard P.V., Seidman E.G., Kam L.Y., Abreu M.T., et al. 6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease. Gastroenterology 122 (2002) 904-915
6. Sandborn W.J. Rational dosing of azathiopurine and 6-mercaptopurine. Gut 48 (2001) 591-592
7. Hibi T., Iwao Y., Yajima T., Inoue N., Ueno Y., Takaishi H., et al. Immunosuppressive agents in the treatment of Crohn's disease and ulcerative colitis. J Gastroenterol 30 Suppl VIII (1995) 121-123
8. Naganuma M., and Hibi T. Do immunosuppressants really works as maintenance therapy after the achievement of remission of severe ulcerative colitis?. J Gastroenterol 37 (2002) 315-317
9. Elion G.B. The pharmacology of azathioprine. Ann NY Acad Sci 21 (1997) 401-407
10. Mawatari H., Yasuhiro K., Nishimura S., Sakura N., and Ueda K. Reversed-phase high-performance liquid chromatographic assay method for quantitating 6-mercaptopurine and its methylated and non-methylated metabolites in a single sample. J Chromatogr B Biomed Sci Appl 716 (1998) 392-396
11. Ishioka S., Hiyama K., Sato H., Yamanishi Y., McLeod H.L., Kumagai K., et al. Thiopurine methyltransferase genotype and the toxicity of azathioprine in Japanese. Intern Med 38 (1999) 944-947
12. Kornbluth A., Present D.H., Lichtiger S., and Hanauer S. Cyclosporin for severe ulcerative colitis: a user's guide. Am J Gastroenterol 92 (1997) 1424-1428
13. Best W.R., Becktel J.M., Singleton J.W., and Kern Jr. F. Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology 70 (1976) 439-444
14. Cuffari C., Hunt S., and Bayless T. Utilization of erythrocyte 6-thioguanine metabolite levels to optimize azathioprine therapy in patients with inflammatory bowel disease. Gut 48 (2001) 642-646
15. Krynetski E.Y., and Evans W.E. Genetic polymorphism of thiopurine S-methyltransferase: molecular mechanisms and clinical importance. Pharmacology 61 (2000) 136-146
16. Tai H.L., Krynetski E.Y., Yates C.R., Loennechen T., Fessing M.Y., Krynetskaia N.F., et al. Thiopurine S-methyltransferase deficiency: two nucleotide transitions define the most prevalent mutant allele associated with loss of catalytic activity in Caucasians. Am J Hum Genet 58 (1996) 694-702
17. Lennard L., Van Loon J.A., and Weinshilboum R.M. Pharmacogenetics of acute azatioprine toxicity: relationship to thiopurine methyltransferase genetic polymorphism. Clin Pharmacolo Ther 46 (1989) 149-154
18. Weinshilboum R.M., and Sladek S.L. Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet 32 (1980) 651-652
19. Zimm S., Collins J.M., Riccardi R., O'Neill D., Narang P.K., Chabner B., et al. Variable bioavailability of oral mercaptopurine. Is maintenance chemotherapy in acute lymphoblastic leukemia being optimally delivered?. N Engl J Med 308 (1983) 1005-1009
20. Van Os E.C., Zins B.J., Sandborn W.J., Mays D.C., Tremaine W.J., Mahoney D.W., et al. Azathioprine pharmacokinetics after intravenous, oral, delayed release oral and rectal foam administration. Gut 39 (1996) 63-68
21. Szumlanski C.L., and Weinshilboum R.M. Sulphasalazine inhibition of thiopurine methyltransferase: possible mechanism for interaction with 6-mercaptopurine and azathioprine. Br J Clin Pharmacol 39 (1995) 456-459
22. Present D.H., Meltzer S.J., Krumholz M.P., Wolke A., and Korelitz B.I. 6-Mercaptopurine in the management of inflammatory bowel disease: short- and long-term toxicity. Ann Intern Med 111 (1989) 641-649